Iressa
gefitinib · AstraZeneca AB
AUTHORISED IN THE EUWhat Iressa is used for
Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Iressa
- Active substance
- gefitinib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01XE02
- Marketing authorisation holder
- AstraZeneca AB
- Authorised in the EU since
- 2009
Official information
In the USA
Same active substance: Iressa
In India
- Gefitinib: 55 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Iressa used for?
Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.
What is the active substance in Iressa?
Iressa contains gefitinib.
Who makes Iressa?
The EU marketing authorisation holder is AstraZeneca AB.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU